News

Powerful beginning: Great funding success for MedKitDoc and Adiposs

What a great start to the new year! 2 start-ups in our portfolio already secured themselves funding for 2022.

The winner of the EIT Health Headstart Award 2020, MedKitDoc, recently secured €7M in its Seed round of funding. The amount was invested by Vorwerk Ventures and Acton Capital, along with existing investor Picus Capital. Besides, FlixBus founders Daniel Krauss and Jochen Engert also participated in the round.

The Berlin-based company´s goal is to put the quality of care above the geographical proximity of a provider and to reduce inefficiencies and waiting times in health care. They developed a platform that redesigned digital consultation sessions in a revolutionary way, with expanding remote medical consultation by connecting doctors, patients and medical devices.

“Digitisation has transformed numerous industries, but healthcare is still in the infancy of its transformation. Corona has had a strong impact not only on the number of innovative solutions emerging but also on regulatory issues that are being resolved combined with an increasing acceptance for digital solutions among the population.”-said Sascha Günther, Principal at Vorwerk Ventures, about the investment.

Another great news for the new year is that EIT Health Catapult 2021 participant Adiposs raised CHF 1.8M Pre-Series A funding led by Privilège Ventures, a Swiss-based venture capital firm focused on seed and early-stage investments.

The Adiposs team is developing ImageBAT, the first product that can detect body wasting in cancer and chronic disease patients before irreversible weight loss, and when treatments are still effective. The imageBAT-enhanced medical scan is fast, pain-free and will be available in every hospital worldwide. By making body wasting visible early, Adiposs enables early treatment for millions of patients, giving them better and longer lives.

The investment round will be used to manufacture the first batch of ImageBAT, a first-in-class contrast agent for brown adipose tissue detection, as well as to perform the first-in-human clinical trial.

“The first equity financing round will allow us to achieve two crucial development milestones and become a clinical-stage company,”-said Andrej Babic, CEO of Adiposs.